Cover Image

Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually

A record number of 40 829 hematopoietic stem cell transplantation (HSCT) in 36 469 patients (15 765 allogeneic (43%), 20 704 autologous (57%)) were reported by 656 centers in 47 countries to the 2014 survey. Trends include: continued growth in transplant activity, more so in Eastern European countri...

Full description

Saved in:
Bibliographic Details
Main Authors: Passweg, Jakob R. (Author) , Dreger, Peter (Author)
Format: Article (Journal)
Language:English
Published: 22 February 2016
In: Bone marrow transplantation
Year: 2016, Volume: 51, Issue: 6, Pages: 786-792
ISSN:1476-5365
DOI:10.1038/bmt.2016.20
Online Access:Verlag, Volltext: https://doi.org/10.1038/bmt.2016.20
Verlag, Volltext: https://www.nature.com/articles/bmt201620
Get full text
Author Notes:J.R. Passweg, H. Baldomero, P. Bader, C. Bonini, S. Cesaro, P. Dreger, R.F. Duarte, C. Dufour, J. Kuball, D. Farge-Bancel, A. Gennery, N. Kröger, F. Lanza, A. Nagler, A. Sureda, M. Mohty for the European Society for Blood and Marrow Transplantation (EBMT)
Description
Summary:A record number of 40 829 hematopoietic stem cell transplantation (HSCT) in 36 469 patients (15 765 allogeneic (43%), 20 704 autologous (57%)) were reported by 656 centers in 47 countries to the 2014 survey. Trends include: continued growth in transplant activity, more so in Eastern European countries than in the west; a continued increase in the use of haploidentical family donors (by 25%) and slower growth for unrelated donor HSCT. The use of cord blood as a stem cell source has decreased again in 2014. Main indications for HSCT were leukemias: 11 853 (33%; 96% allogeneic); lymphoid neoplasias; 20 802 (57%; 11% allogeneic); solid tumors; 1458 (4%; 3% allogeneic) and non-malignant disorders; 2203 (6%; 88% allogeneic). Changes in transplant activity include more allogeneic HSCT for AML in CR1, myeloproliferative neoplasm (MPN) and aplastic anemia and decreasing use in CLL; and more autologous HSCT for plasma cell disorders and in particular for amyloidosis. In addition, data on numbers of teams doing alternative donor transplants, allogeneic after autologous HSCT, autologous cord blood transplants are presented.
Item Description:Gesehen am 14.08.2019
Physical Description:Online Resource
ISSN:1476-5365
DOI:10.1038/bmt.2016.20

Similar Items